2020
Targeted Therapies in Advanced Gastric Cancer
Patel TH, Cecchini M. Targeted Therapies in Advanced Gastric Cancer. Current Treatment Options In Oncology 2020, 21: 70. PMID: 32725377, DOI: 10.1007/s11864-020-00774-4.Peer-Reviewed Original ResearchConceptsGastric cancerMetastatic diseaseClinical trialsVascular endothelial growth factor receptor inhibitorDeath ligand 1 (PD-L1) statusEndothelial growth factor receptor inhibitorImmune checkpoint inhibitor pembrolizumabHuman epidermal growth factor 2Epidermal growth factor 2Growth factor receptor inhibitorsBackbone of therapyCheckpoint inhibitor pembrolizumabCombination immune therapyThird-line settingFirst-line settingSecond-line settingAddition of trastuzumabPD-L1 statusAdvanced gastric cancerMetastatic gastric cancerHER2-positive tumorsSquamous cell carcinomaFuture clinical trialsNumerous clinical trialsStandard of care
2017
Olaratumab for the treatment of soft tissue sarcoma.
Deshpande HA, Cecchini M, Ni Choileain S, Jones R. Olaratumab for the treatment of soft tissue sarcoma. Drugs Of Today 2017, 53: 247-255. PMID: 28492292, DOI: 10.1358/dot.2017.53.4.2560077.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasPhase II studyTissue sarcomasII studyMetastatic diseaseOverall survivalOngoing phase III studiesRandomized phase II studyPlatelet-derived growth factor receptor alphaProgression-free survivalPhase III studyStandard chemotherapy regimensGrowth factor receptor alphaUnited States FoodMechanism of actionChemotherapy regimensIII studyOngoing trialsSolid malignanciesReceptor alphaPhase IbDrug AdministrationSignificant improvementFDA approvalOlaratumab